Minimal residual disease negativity predicts time to next treatment in multiple myeloma

For patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTNT), according to a study published online March 6 in Blood Cancer Journal.

Leave A Comment

Your email address will not be published. Required fields are marked *